Sorafenib (Nexavar): FDA Approval, Licensing in Türkiye, and Reimbursement Status
In this article
Nexavar (Sorafenib) Drug Profile
- FDA Approved: Yes (first approval date: December 20, 2005)
- Brand Name: Nexavar
- Active Ingredient: Sorafenib
- Administration: Taken as oral tablets.
- Category: Targeted therapy agent
- Manufacturer: Bayer HealthCare Pharmaceuticals Inc.
- Distribution in Türkiye: Bayer
- Approved Cancer Types:
- Advanced renal cell carcinoma (kidney cancer)
- Unresectable hepatocellular carcinoma (liver cancer)
- Progressive, locally recurrent or metastatic differentiated thyroid carcinoma resistant to radioactive iodine
What Is Sorafenib and How Does It Work?
Sorafenibis an oral targeted cancer medicine used for advanced cancers. A multikinase inhibitor , it suppresses cell growth signaling and tumor formation of new blood vessels (angiogenesis).
1. Inhibition of Cell Proliferation: Sorafenib targets the intracellular RAF/MEK/ERK signaling pathway. Inhibiting serine/threonine kinases such as BRAF and CRAF (RAF-1) arrests the cell cycle. This effect is particularly pronounced in cells carrying mutant BRAF.
2. Inhibition of Angiogenesis: Inhibiting receptor tyrosine kinases such as VEGFR-2, VEGFR-3, and PDGFR-β prevents new blood vessels that supply tumors with oxygen and nutrients and reduces endothelial cell migration.
FDA (United States Food and Drug Administration) Approval History
- December 20, 2005: Approved for advanced renal cell carcinoma.
- November 19, 2007: Approved for hepatocellular carcinoma.
- November 22, 2013: Approved for differentiated thyroid cancer.
Licensing and Reimbursement in Türkiye
Nexavar is licensed by the Turkish Ministry of Health for the following therapeutic indications:
- Metastatic renal cell carcinoma unresponsive to interferon alfa or interleukin-2.
- Hepatocellular cancer unsuitable for local treatment, with Child-Pugh A functional liver reserve.
- Radioactive iodine-resistant, locally relapsed or metastatic differentiated thyroid cancer, as monotherapy until progression.
Reimbursement: SGK reimburses it in Türkiye for certain indications and under specified conditions.
Price: As of December 2025, the retail pharmacy cost of Nexavar 200 mg, 112 film-coated tablets, representing one cycle, is 36574.23 TL.
Mechanisms of Resistance
- Changes in target proteins: RAF kinase mutations may prevent drug binding; cells may continue growing without the inhibited pathway.
- Activation of alternative signaling pathways: When RAF/MEK/ERK is suppressed, PI3K/AKT/mTOR and other growth pathways may activate.
- Compensatory angiogenesis: Despite VEGF inhibition, tumors may increase alternative factors such as FGF, PDGF, or ANGPT2 .
- Drug Efflux: Increased transport proteins such as P-glycoprotein (P-gp) expel the drug from cells.
- Microenvironmental Adaptation: In low-oxygen conditions, increased HIF-1α may permit escape from drug effects.
Pharmacokinetics
| Absorption | Oral bioavailability is 38–49%. Because food reduces absorption, take it on an empty stomach . Maximum plasma concentrations are reached in ~3 hours. |
| Distribution | Plasma protein binding ~99.5%. Volume of distribution is large; blood–brain barrier penetration is limited. Half-life is 25–48 hours. |
| Metabolism | Mainly metabolized in the liver by CYP3A4 and UGT1A9 . It has at least 8 metabolites, the most active being N-oxide (M-2) . |
| Elimination | Elimination is mainly hepatic. Of the dose, 77% is excreted in feces and 19% in urine. |
How Is It Taken? Dose Range
- 400 mg twice daily (total 800 mg/day), approximately 12 hours apart.
- Take on an empty stomach: At least 1 hour before or 2 hours after food.
- Swallow tablets whole with plenty of water; do not chew or break them.
Drug Interactions
- CYP3A4 Interactions: Ketoconazole and ritonavir may increase levels; rifampicin, phenytoin, and St. John's wort may reduce effectiveness.
- UGT1A9 Inhibitors: Atazanavir and mefenamic acid may increase levels.
- Anticoagulants (Warfarin): Increased INR and bleeding risk.
- Transporters (P-gp): Verapamil and amiodarone increase absorption; rifampicin reduces it.
- Chemotherapy Medicines: Doxorubicin, irinotecan, and capecitabine may increase toxicity.
Precautions
- Liver Impairment: Use cautiously in Child-Pugh B and C patients; monitor liver tests regularly.
- Hypertension: Risk is high in the first 6 weeks; monitor blood pressure regularly.
- Skin Toxicity: Hand–foot syndrome is common; severe cases require dose adjustment.
- Surgery: Stop at least 2 weeks before surgery and restart when the wound has healed.
- Heart: QT prolongation may occur; monitor ECG.
- Pregnancy: Category D; contraindicated during pregnancy and breastfeeding.
Adverse Reactions
The most frequently reported reactions and rates are:
- Diarrhea (39%)
- Fatigue (22%)
- Hand–foot syndrome (21%)
- Skin rash (16%)
- Hair loss (14%)
- Reduced appetite (14%)
- Nausea (11%)
- Weight loss (9%)
- Dry skin (8%)
- Itching (8%)
- Abdominal pain (8%)
- Bleeding (7%)
- Voice changes (6%)
- Vomiting (5%)
- High blood pressure (5%)
- Liver injury (<1%)
Approximately 29% of patients discontinue treatment because of serious adverse reactions. Follow-up should include liver tests, complete blood counts, and thyroid function.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.